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Abstract
Background: The onset of coeliac disease (CD) in the first year of life is uncommon and the diagnosis can be
challenging due to the suboptimal sensitivity of tissue transglutaminase antibodies (tTG) at this age and the
many other possible causes of malabsorption in infants. Antibodies to deamidated gliadin peptides (anti-DGPs), especially
IgG, may appear earlier than IgA anti-tTG in very young children with CD.
Case presentation: We report here on an 8-month-old child who was evaluated for failure to thrive, constipation and
developmental delay. The symptoms started following gluten introduction in the diet. Laboratory tests showed high fecal
elastase concentration, normal serum IgA levels with positive IgG and IgA anti-DGPs, whereas anti-tTG were not detected.
The duodenal biopsy revealed a complete villous atrophy (Marsh-Oberhuber 3C). The culture of biopsy fragments in the
presence of gliadin peptides did not stimulate the production of IgA anti-endomysial antibodies. Genetic testing proved
the child was positive for HLA-DQ2 (DQA1*05; DQB1*02) and HLA-DQ8 (DQA1*03, DQB1*0302). Having initiated the
gluten-free diet, the symptoms disappeared and the infant experienced rapid catch-up growth with normalization of
psychomotor development.
Conclusions: This case report highlights the utility of anti-DGPs for screening infants with suspected CD. The pattern
with positivity for IgG and IgA anti-DGPs only is rare in IgA-competent children with biopsy-proven CD. It could be
explained in infancy as immaturity of the adaptive immune system.
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Background
Coeliac disease (CD) is an autoimmune disorder
triggered by gluten ingestion in genetically predisposed
subjects [1]. While it is know to affect around 1% of
Caucasian schoolchildren, the true prevalence is prob-
ably underestimated [2, 3]. While coeliac disease can
occur at any age following gluten introduction in the
diet, the onset of symptoms shortly after weaning is un-
common [4–6]. The pathogenesis of the disease depends
on the presence of gliadin-reactive CD4+ T cells in the
lamina propria of the small bowel, which recognize glia-
din peptides deamidated by tissue transglutaminase and
bound to DQ2+ or DQ8+ antigen-presenting cells [7, 8].
The gliadine-reactive CD4+ T cells enhance an adaptive
immune response that leads to intraepithelial and
lamina propria infiltration of inflammatory cells, crypt
hyperplasia, and villous atrophy [9]. Innate immunity
also contributes to mucosal damage [10]. Tissue trans-
glutaminase antibodies (tTG) are directed against the
enzyme responsible for the deamidation of gliadin in the
lamina propria. These antibodies perform at a lower
sensitivity and specificity in children under 18 months of
age compared to older subjects, the earliest tTG
seropositivity being reported at the age of 12 months
[11–14]. Tests for antibodies to deamidated gliadin pep-
tides (anti-DGPs) have replaced those for anti-gliadin
antibodies, as the former show higher specificity [15].
Immunoglobulin G anti-DGPs are more sensitive than
IgA in the diagnosis of CD [16–19]. The combination of
IgA anti-tTG and IgG anti-DGP offers the best accuracy
for diagnosis of CD at all ages, as it increases the
chances of detecting the disease in subjects with IgA de-
ficiency [17, 20–23]. Moreover, the presence of IgG anti-
DGPs seems to be the best serologic marker of villous
atrophy in the follow up of coeliac patients [24–26].
While in older patients IgA anti-tTG levels generally
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correlate with the severity of the duodenal lesions
according to the Marsh–Oberhuber grading system
[27, 28], in young children high IgG anti-DGP titres
are related to severe intestinal damage [29–32].
In this article we present the unusual case of an infant
who developed symptoms of CD shortly after weaning.
In spite of a complete villous atrophy at biopsy, only
serum anti-DGPs were increased, whereas anti-tTG and
anti-endomysial antibodies were absent.
Case presentation
An 8-month-old boy was evaluated for failure to thrive
and developmental delay. He was born at 38 weeks of
gestational age (birth weight 4.090 kg, above the 90th
percentile). Familial and antenatal history was unremark-
able; in particular there was no history of gestational dia-
betes nor any significant perinatal event. The patient
had been exclusively breastfed for the first 5 months of
life, with regular growth and psychomotor development.
After weaning, at between 6 and 8 months of age, the
child experienced worsening constipation, bulky stools,
irritability and anorexia. The onset of symptoms had no
association with any specific event. The infant was ad-
mitted to the pediatric ward of the University Hospital
of Udine, Italy, when he was 8-months old. His weight-
for-length was below the 3rd percentile, whereas 2
months before it was at the 25th percentile [33].
Between the 6th and 8th months he also showed devel-
opmental regression: his babbling and smiling decreased,
he could no longer sit without support and became
apathetic and irritable. The head circumference had in-
creased normally since birth at around the 25th percent-
ile. The physical examination revealed severe dystrophy,
with a potbelly and wasted limbs. He appeared apathetic
with little interest in things and people around him. He
also had mild hypotonia, with decreased muscle bulk
but preserved deep tendon reflexes. Laboratory tests re-
vealed a normal full blood count. A metabolic panel
showed serum albumin (3.6 g/dL;), Vitamin A (207 mcg/
L) and total IgG (269 mg/dL) levels at the lower limit of
normal. A screening for CD revealed normal IgA levels,
absence of tTG antibodies but positive serum anti-DGPs
(IgG 183 U/mL; IgA 147 U/mL; normal range < 10 U/
ml for both, as suggested by the manufacturer). Tissue-
tranglutaminase antibodies and anti-DGPs were assessed
by a chemiluminescence enzyme immunoassay (Zenit-
RA®, Menarini Diagnostics, Florence, Italy). All other
laboratory tests of the metabolic panel were normal
(including iron levels, folic acid, vitamin D, B12, and E,
thyroid-stimulating hormone, creatinine kinase, venous
blood gas, lactate and ammonia levels). Fecal elastase
was at a low concentration (<100 mcg/g), while fecal
calprotectin concentration (IDK® Calprotectin ELISA,
Immundiagnostik, Bensheim, Germany) of 135 mg/kg
was in the normal range for the patient’s age [34, 35]. A
normal sweat chloride test ruled out cystic fibrosis and a
magnetic resonance imaging of the brain excluded struc-
tural/anatomic brain abnormalities.
An esophagogastroduodenoscopy with duodenal biopsy
showed complete villous atrophy with crypt hypertrophy
and more than 60 intraepithelial lymphocytes per 100
enterocytes in the duodenal mucosal, corresponding to a
3C score of the Modified Marsh (Oberhuber) classifica-
tion. Antiendomysial IgA antibodies were not detected in
the supernatant of duodenal mucosal fragments cultured
with gliadin peptides [36]. Genetic analysis revealed the
presence of HLA-DQ2 (DQA1*05; DQB1*02) and HLA-
DQ8 (DQA1*03; DQB1*0302). Within 4 months of initiat-
ing a gluten-free diet, the child caught up with his original
weight-for-age z-score, with complete normalization of
neurological evaluation and laboratory parameters. Six
months after the diagnosis, IgG anti-DGP were still
slightly positive (20 UI/ml, normal range < 10 UI/ml),
while IgA anti-tTG were absent. After 6 months and
for the next 2 years both DGP and tTG antibodies
resulted negative.
Discussion
In this case report, the serological pattern with DGP-
positive/tTG-negative antibodies in an infant was pre-
dictive of CD with villous atrophy. The finding confirms
evidence from literature that anti-DGPs are a sensitive
marker of CD in very young children and may be the
first CD antibodies to seroconvert [37, 38]. This would
be in accordance with the suggested pathogenesis of CD,
as the disease process seems to initiate with the T-cell
responses to deamidated gliadin peptides in the intestinal
mucosa [39]. However, only a minority of children with
circulating T cells specific to deamidated gliadin will
develop anti-DGPs and celiac disease. Peripheral blood T-
cell responses to deamidated gliadin peptides were detect-
able at 9 months of age in 40% of a cohort including 300
children with HLA-associated genetic risk for CD. How-
ever only 3.1% of the cohort’s subjects had developed CD
by the age of 4 years, each being seropositive for IgG anti-
DGPs and IgA anti-tTG at the time of diagnosis [40].
Lammi et al. showed that in 35 of the 48 children with
CD from the Finnish DIPP study [41], serum IgG anti-
DGPs preceded tTG positivity and appeared on average
1 year earlier [19]. Our patient, unlike the children with
anti-DGPs seropositivity and CD described by Lammi et
al. [19], never developed tTG antibodies in spite of
severe gluten-sensitive enteropathy.
The positivity of serum anti-DGPs only in very young
children has a poor positive predictive value for CD and
should be considered with caution: in a retrospective ana-
lysis, Parizade found that over 60% of children under 2 years
of age with DGP-positive/tTG-negative pattern (HLA
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alleles not reported) became seronegative within 1 year,
without following a gluten-free diet [42]. In that study, 6
out of 12 children with only anti-DGP positivity referred
for biopsy, had a diagnosis of CD [42]. In the study by Olen
and colleagues, [43] villous atrophy was found only in 8 of
149 children with DGP-positivity and tTG-negativity. These
findings would suggest duodenal biopsy may be indicated
in infants with sole anti-DGP positivity only if they have
signs/symptoms consistent with CD and positivity for HLA
DQ2/DQ8, as was the case in our patient [42, 44].
The children reported here was at standard genetic
risk of CD, given the presence of the HLA-DQ2
(DQA1*05; DQB1*02) and HLA-DQ8 (DQA1*03,
DQB1*0302) [4], while in a case-control study by
Megiorni et al. [45], the HLA haplotype with copresence
of DQ2 and DQ8 resulted at the top of the genetic risk
gradient for CD (risk 1:7).
The infant’s fecal elastase was low, with chronic mal-
absorption. In subjects with villous atrophy, the mucosal
damage may impair the release of enteric hormones
(secretin and cholecystokinin) and cause secondary re-
duction of exocrine pancreatic secretion, which includes
fecal elastase [46–50]. However in children with CD,
fecal elastase concentration usually normalizes after a
few months from the introduction of a gluten free diet
[51], as in the case presented here.
The patient described in this paper had neurological
symptoms at presentation, such as developmental delay
and hypotonia. These symptoms are sometimes reported
in children with onset of CD during infancy, possibly due
to vitamin and micronutrient deficiency [52]. In our pa-
tient, no such nutritional deficit was identified although
zinc levels, which are linked to neurocognitive delay in
malnourished children, could not be investigated [53].
Timing of gluten introduction in our patient was in
accordance with current international recommendations
[37] and could not influence the onset of CD. However,
recent evidence indicates that neither early (<17 weeks
of life) nor delayed gluten introduction (>26 weeks) is a
risk factor for future CD [54].
Conclusions
This case report highlights the utility of IgG anti-DGPs for
screening infants with suspected coeliac disease. Some of
the children who develop CD at this age, might have an im-
mature adaptive immune response with the sole production
of anti-DGPs even in the presence of villous atrophy, as
was the case in our patient. We suggest that the serologic
pattern with DGP-positive/tTG-negative antibodies in an
infant with consistent symptoms and HLA DQ2/DQ8
haplotype should prompt a duodenal biopsy to rule out
CD. Further studies are needed to provide a more detailed
evaluation of this serologic pattern in IgA-competent
children with celiac disease.
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